UPDATE: Barclays Starts TiVo (TIVO) at Overweight; Cash Flow Finally Going Positive
Get Alerts TIVO Hot Sheet
Price: $6.09 --0%
Rating Summary:
10 Buy, 11 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 8
Rating Summary:
10 Buy, 11 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 8
Join SI Premium – FREE
(Updated - July 10, 2012 2:48 PM EDT)
Barclays initiates coverage on TiVo (NASDAQ: TIVO) with an Overweight. PT $11.00.
Analyst, Kannan Venkateshwar, said, "After a decade of losses, we expect TiVo's EBITDA margins and cash flows to finally become positive over the next 18 months...We also expect the successful resolution of TiVo's intellectual property litigation to provide further upside, with settlements likely with Verizon (NYSE: VZ) and Time Warner Cable (NYSE: TWC)."
For an analyst ratings summary and ratings history on TiVo click here. For more ratings news on TiVo click here.
Shares of TiVo closed at $7.91 yesterday.
Barclays initiates coverage on TiVo (NASDAQ: TIVO) with an Overweight. PT $11.00.
Analyst, Kannan Venkateshwar, said, "After a decade of losses, we expect TiVo's EBITDA margins and cash flows to finally become positive over the next 18 months...We also expect the successful resolution of TiVo's intellectual property litigation to provide further upside, with settlements likely with Verizon (NYSE: VZ) and Time Warner Cable (NYSE: TWC)."
For an analyst ratings summary and ratings history on TiVo click here. For more ratings news on TiVo click here.
Shares of TiVo closed at $7.91 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Barclays Upgrades Akzo Nobel NV (AKZA:NA) (AKZOY) to Overweight
- Piper Sandler Starts Jasper Therapeutics (JSPR) at Overweight
- Barclays sees upside for Alibaba, Churchill Downs
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share